Merck KGaA

Overview

Date Founded

1995

Headquarters

Frankfurter Strasse 250, Darmstadt, 64293, DEU

Type of Company

Public

Employees (Worldwide)

57K

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate & Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.

Website

http://www.merck.de

Contact Data

Trying to get in touch with decision makers at Merck KGaA? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!

In The News

FierceBiotech

January 22, 2021

GlaxoSmithKline's R&D failures rack up, notching an Immutep-partnered trial cull

FiercePharma

January 21, 2021

GlaxoSmithKline's ‘serial disappointments' cast doubt on its growth plans: analyst

Business Wire

January 21, 2021

Global Cancer Gene Therapy Market Research during 2021-2025 | Industry Planning Analysis for the New Normal | Technavio

GlobeNewswire

January 21, 2021

1,3-Propanediol Market Research Report by Production, by Sales, by End-Use Verticals, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19

FierceBiotech

January 20, 2021

GSK, German Merck's $4.2B bintrafusp alfa drug a bust, fails to beat king Keytruda in lung cancer

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.

Executives & Employees

Stefan Oschmann

Chief Executive Officer

Belén Garijo López

Chief Executive Officer

Marcus Kuhnert

Chief Financial Officer

Dirk Toepfer

Chief Information Officer

Isabel de Paoli

Chief Strategy Officer & Executive Vice President

Dietmar Eidens

Chief Human Resources Officer

Bernd Reckmann

Chief Executive Officer, Life Science & Performance Materials

Kai Beckmann

Chief Executive Officer, Performance Materials

Uta Kemmerich-Keil

Chief Executive Officer of Consumer Health

Jitinder Saini

Global Chief of Staff & Head-Strategy Realization Office

Supervisory Board

Wolfgang Heinz Büchele

Chief Executive Officer at Exyte AG

Helga Ruebsamen-Schaeff

Professor at Johann Wolfgang Goethe-Universität Frankfurt am Main

Edeltraud Glänzer

Deputy Chairman of the Supervisory Board at Evonik Industries AG

Dietmar Oeter

Vice President, Corporate Quality Assurance at Merck KGaA

Jürgen Glaser

District Manager at Industriegewerkschaft Bergbau Chemie Energie

Alexander Putz

Professional at Merck KGaA

Gabriele Eismann

Global Product Manager, Inorganic Reagents at Merck KGaA

Michael Fletterich

Chairman, Works Council Merck Darmstadt & Gernsheim at Merck KGaA

Helene von Roeder

Chief Financial Officer at Vonovia SE

Christian Raabe

Former Director-Investor Relations at Merck KGaA

Trending Organizations

Paths to Merck KGaA

Potential Connections via
Relationship Science

You

Merck KGaA

Owners & Shareholders

Details Hidden

Select Equity Group LP

SEG offers a long-only equity management program that utilizes fundamental analysis to select stocks they believe will provide better than market returns over a complete market cycle. Money market reserves may comprise 0 to 50 percent of the account, but generally range from 0 to 20 percent, depending on market conditions. SEG generally limits their portfolio of securities to less than 40 than stocks in each account. SEG employs eight primary investment strategies. Their investment strategies are generally driven by a research-intensive, fundamental bottom-up process and draw upon a centralized research department. These strategies include: Small-Mid Cap /Long-Only, US Core, Concentrated Opportunistic, US Long/Short, International Long/Short, International Long-Only, Global Long-Only, and Private Equity. SEG obtains exposure to particular issuers or securities for their private funds (and may for individual clients) through various types of derivatives transactions, including swaps and contracts for differences. In addition, they may hedge exposure to currency fluctuations for foreign securities owned by the private funds by entering into currency forward or option transactions.

Details Hidden

Amundi Asset Management SA (Investment Management)

Amundi-IM invests through funds in all asset classes and main currencies. The firm believes that overall analysis of a company, including economic, social and environmental aspects, allows for better assessment of the risks and opportunities that may affect its long-term valuation.

Details Hidden

Degroof Petercam Asset Management SA

Degroof Petercam AM aims to capitalize on market inefficiencies through in-house research and a focus on valuation and fundamentals. Their investment process allows them to capitalize on market inefficiencies at all stages of the investment cycle and under different market conditions, seeking to generate consistent and risk-controlled outperformance. They focus on the European market and have dedicated SRI expertise in equities and government bonds. The firm conducts in-house macroeconomic research, investment-related research and financial analysis to invest in a range of assets including equity, fixed-income, real estate and money market products and balanced or specialized mandates. They employ a team-driven decision-making process where members work in close collaboration. Degroof Petercam AM follows bottom-up and top-down approaches to constructs diversified portfolios without excessive risk-taking. They tactically allocate assets and utilize a behavioral value approach based on quantitative and qualitative criteria to select shares.

Recent Transactions

Details Hidden

EMD Millipore Corporation, Merck KGaA purchase RESOLUTION Spectra Systems SAS

Details Hidden

FlexEnable Ltd., Plastic Logic JSC purchase Merck KGaA /Otft Materials Portfolio from Merck KGaA

Details Hidden

EMD Millipore Corporation, Merck KGaA purchase FloDesign Sonics, Inc. from Bright Capital LLC, Dynamk Capital

Transaction Advisors

Accountant

KPMG LLP

Advised onClayton Dubilier & Rice LLC purchases VWR International LLC from Merck KGaA

Legal Advisor

Allen & Overy LLP

Advised onMerck KGaA purchases Sigma-Aldrich Corp.

Investment Advisor

Guggenheim Securities LLC

Advised onMerck KGaA purchases Sigma-Aldrich Corp.

Legal Advisor

Hilary S. Foulkes

Advised onMerck KGaA purchases Sigma-Aldrich Corp.

Legal Advisor

Peter Allan Atkins

Advised onMerck KGaA purchases Sigma-Aldrich Corp.

Legal Advisor

David A. Martland

Advised onLuminex Corp. purchases EMD Millipore Corp. /Flow Cytometry Assets from Merck KGaA

Advisors & Consultants

Advisor

Marla Kaplowitz

President & Chief Executive Officer at American Association of Advertising Agencies

Legal Advisor

Steven Buffone

Senior Advisor at Keystone National Properties

Legal Advisor

James C. Colihan

Managing Partner at Baker & McKenzie LLP

Clients

Seagen Inc.

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Pfizer, Inc.

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Biogen, Inc.

Biogen has some of the world’s best neurologists and neuroscientists. They engage with physicians and scientific leaders around the world with the aim to further medical research. Their focus on neuroscience, their deep scientific expertise and courage to take risks makes them leaders in the research and development of medicines to transform neuroscience to benefit society. Their technology and engineering capabilities create novel ways to seamlessly transition products from development to manufacturing with the intent of bringing their high-quality medicines to market faster. They respect the contributions of health care providers caring for people living with neurological diseases. They honor the important role of caregivers, families and friends who care about them.

Key Stats and Financials As of 2019

Market Capitalization

$77.2B

Total Enterprise Value

$66.6B

Earnings Per Share

$3.47

EBITDAMargin

24.18%

Enterprise Value / Sales

3.61x

Enterprise Value EBITDAOperating

14.91x

TEVNet Income

44.12x

Debt TEV

0.23x

Three Year Compounded Annual Growth Rate Of Revenue

2.44%

Revenue

$18.5B

Net Profit

$1.51B

EBITDA

$4.46B

Total Debt

$15.1B

Total Equity

$20.5B

Non-Profit Donations & Grants

$10K

2016

American Red Cross Eastern Missouri

Non-Profit Donations & Grants Received

$248K

12/31/2017

Bill & Melinda Gates Foundation

$1.15M

12/31/2013

Bill & Melinda Gates Foundation

Investments

Details Hidden

BioVascular, Inc.

BioVascular, Inc. develops drugs and devices for control of intimal hyperplasia associated with vascular procedures. It is a integrated specialty cardiovascular therapeutic company, and to utilize corporate partnerships in markets that have complex marketing barriers and/or combination technologies. The company was founded by John H. Parrish and Paul F. Glidden in 2005 and is headquartered in San Diego, CA.

Details Hidden

Verva Pharmaceuticals Ltd.

Verva Pharmaceuticals Ltd. developed therapies to treat diabetes. Its products include insulin sensitizers, insulin secretagogues, fat formation inhibitors for the prevention, treament of obesity, drug-induced weight gain and insulin secretion modulators. The company was founded in 1996 and was headquartered in Geelong, Australia.

Details Hidden

Archemix Corp.

Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA.

Investors

Details Hidden

David Burgstahler

Co-Founder at Avista Capital Partners

Suppliers

Bristol-Myers Squibb Company Medical Support Services | New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Eli Lilly & Company Hospitals & Patient Services

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Juniper Pharmaceuticals, Inc. Biotechnology | Boston, MA

Columbia Laboratories has a rich heritage in pharmaceutical research and development that has helped place the company on the forefront of women's healthcare and drug delivery. Our products use the principles of bioadhesion to achieve controlled, sustained delivery of hormones and other compounds that are difficult to administer.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.